<DOC>
	<DOCNO>NCT00211432</DOCNO>
	<brief_summary>The purpose study provide compassionate use anecortave acetate sterile suspension 15 mg series five patient mean control pseudovitelliform detachment .</brief_summary>
	<brief_title>Treatment Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg )</brief_title>
	<detailed_description />
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>1 . Clinical diagnosis patient pseudovitellium detachment . 2 . Patients must least 18 year age . 3 . Visual acuity 20/30 20/320 study eye Early Treatment Diabetic Retinopathy Study ( ETDRS ) visual acuity chart 4 . Visual acuity 20/800 good fellow eye ETDRS visual acuity chart 1 . Patient significantly compromise visual acuity study eye due concomitant ocular condition . 2 . Patients undergone intraocular surgery within last 2 month . 3 . Patient participate investigational drug study . 4 . Use investigational drug treatment relate unrelated condition within 30 day prior receipt study medication . 5 . Inability obtain photographs document choroidal neovascularization ( CNV ) ( include difficulty venous access ) . 6 . Patient significant liver disease uremia . 7 . Patient known adverse reaction fluorescein indocyanine green iodine . 8 . Patient history medical condition would preclude schedule visit completion study 9 . Patient insertion scleral buckle study eye 10 . Patient receive radiation treatment 11 . Patient anticoagulant therapy exception aspirin 12 . Patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>